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肿瘤坏死因子（tumor necrosis factor ，TNF）家族能够调节多种生理活动，
例如：细胞生长、分化，细胞存活、凋亡，产生细胞因子以及淋巴细胞的共刺激
作用等等。TNFR 家族有四种诱骗受体：DcR1、DcR2、DcR3 和 OPG。DcR3 又
称 TR6，是新近发现的一个新的 TNFR 超家族成员。它能竞争性地与 LIGHT 










为了研究 DcR3 及 ERK1/2 在胃癌发生发展中的作用及其免疫机制，本实
验首先对临床获取的胃癌肿瘤病人手术切除的组织进行了检测，利用 RT-PCR 
检测肿瘤组织中 DcR3 及 ERK1/2 mRNA 水平的表达，以 Western blot 技术分
析肿瘤组织中 DcR3 及 ERK1/2 蛋白水平的表达情况，并进一步利用免疫组织
化学方法了解 DcR3 及 ERK1/2 在肿瘤组织中的定位情况。获得了临床胃癌病

















和心脏、肝脏等各器官中 DcR3 及 ERK1/2 mRNA 水平、蛋白水平的表达情况
及其在组织中的定位情况。 
实验发现胃癌患者肿瘤组织中 DcR3 和 ERK1/2 mRNA 水平和蛋白水平的
表达量都较癌旁组织有明显上升；利用人胃癌细胞系 BGC823 建立的胃癌裸鼠
模型的肿瘤组织中 DcR3 和 ERK1/2 也出现高表达。比较后可发现在对胃癌动
物模型和临床胃癌患者肿瘤组织的检测中，DcR3 和 ERK1/2 在肿瘤的发生发
展过程中均呈过表达趋势，具有协同表达的特点。因此，在胃癌的发生发展过程
中，DcR3 和 ERK1/2 的表达存在密切联系，进一步研究可对于临床胃癌的早
期诊断和免疫治疗提出一种新的思路。 




































Gastric cancer is one of common malignant tumors in China, is the most common 
gastrointestinal malignancy. Early gastric cancer always with only mild even no 
symptoms, when there is significant symptoms, disease is already advanced. Although 
the precise pathogenesis of gastric cancer is remains unclear, environmental factors, 
genetic factors were central to the mechanism of gastric precancerous lesions and 
tumor development, the immune regulation also plays an important role in the disease 
progression. 
Tumor necrosis factor (TNF) family can regulate multiple physiological activities, 
such as: cell growth, differentiation, cell survival, apoptosis, cytokine production and 
lymphocyte co-stimulation, etc. TNFR family has four decoy receptors: DcR1, DcR2, 
DcR3 and OPG. DcR3, also known as TR6, is a member of TNFR superfamily which 
is newly identified. It could binding with LIGHT or FasL and inhibit LIGHT or 
FasL-mediated apoptosis. Recent studies found that DcR3 could be found highly 
expressed in a variety of tumors and certain autoimmune diseases which would 
promote angiogenesis, induce apoptosis of dendritic cells, inhibit macrophage 
differentiation. 
Extracellular signal-regulated kinase (ERK1/2, p44/p42) is members of a 
mitogen-activated protein kinase ( MAPK) family, widely exist in the human body. 
Through the Ras / Raf / MAPKKK / MAPKK / MAPK / ERK pathway, Ras and other 
genes affected by stimulation, activation of MAPK, ERK1/2 and other pathways to 
promote cell proliferation and differentiation. Recent studies show that, ERK1/2 were 
highly expression in breast cancer, colorectal cancer, pancreatic cancer, bile duct 
cancer, malignant melanoma, leukemia and tumors such as myxoma, which may 
apply as a separate forecast of prognosis in patients with a reference index. 
In order to investigate the effect and immune mechanism that DcR3 and ERK1/2 in 
gastric cancer occur and development, I adopted measures as follow: first, I collected 















ERK1/2 in mRNA level with RT-PCR and Western blot analysis of which expressed 
in protein level, using immunohistochemistry to understand localization of DcR3 and 
ERK1/2 in the tumor tissue. After that, we established nude rats’ gastric cancer 
animal model by injecting human gastric cancer cell lines BGC823, using RT-PCR, 
Western blot, immunohistochemistry to detect expression of DcR3 and ERK1/2 in 
tumor tissue of nude mice and rats’ heart, liver, spleen, lung, kidney and its position 
in the organization situation. 
During the research, I found that expression of DcR3 and ERK1/2 were 
significantly higher than the adjacent tissues in patients with gastric cancer. The 
tumor of animal models which were established with human gastric cancer cell line 
BGC823 also appears highly expression of DcR3 and ERK1/2. DcR3 and ERK1/2 in 
the process of tumor development showed overexpression tendency, has coordinated 
characteristics. Therefore, in the process of development of gastric cancer, DcR3 and 
ERK1/2 expressed closely. Further studies may provide a new diagnosis method or 
immune therapy idea to cure gastric cancer. 
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